We are live on ! Find out more
RGN

REGENERX BIOPHARMACEUTICALS
RGN

Delisted

RGN was delisted on the 22nd of December, 2010.

Back to rankings

5 hedge funds and large institutions have $67K invested in REGENERX BIOPHARMACEUTICALS in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital invested

Capital invested by funds: $33K → $67K (+$34K)

67% more funds holding

Funds holding: 3 → 5 (+2)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PTC
Philadelphia Trust Company
Pennsylvania
+$23K
2
FIM
Frontier Investment Management
Texas
+$16K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
WJA
1
Williams Jones & Associates
New York
$23K – – –
PTC
2
Philadelphia Trust Company
Pennsylvania
$23K +$23K +150,000 New
FIM
3
Frontier Investment Management
Texas
$16K +$16K +100,040 New
DBIA
4
Dumont & Blake Investment Advisors
New Jersey
$3K – – –
CG
5
Colony Group
Massachusetts
$2K – – –

RGN Hedge Fund Activity: Q4 2018 in Review

5 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2018, worth a combined $67K — up 103% from $33K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new RGN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Philadelphia Trust Company, opening a new position worth an estimated $23K.

  • 5 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2018, up from 3 in Q3 2018.
  • Funds reported $67K of REGENERX BIOPHARMACEUTICALS stock for Q4 2018, up 103% quarter-over-quarter.
  • 2 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2018 and 0 closed out, a net change of +2 holders.
  • The largest REGENERX BIOPHARMACEUTICALS buyer in Q4 2018 was Philadelphia Trust Company, an estimated $23K added.

Based on aggregated 13F filings for Q4 2018.